vimarsana.com

Page 3 - ரேமஂட் ஜேம்ஸ் மனிதன் ஆரோக்கியம் புதுமைகள் மாநாடு News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Viking Therapeutics Reports First Quarter 2021 Financial Results and Provides Corporate Update

Viking Therapeutics Reports First Quarter 2021 Financial Results and Provides Corporate Update Conference call scheduled for 4:30 p.m. ET today - U.S. and European Sites Continue to Enroll Phase 2b VOYAGE Study Evaluating VK2809 for the Treatment of NASH - Phase 1 Study Evaluating VK0214 in Healthy Volunteers Ongoing; Expect to Initiate Proof-of-Concept Trial in X-ALD Patients Mid-2021 - Quarter-End Cash Approximately $242 Million; Provides Ample Runway to Achieve Key Clinical Milestones News provided by Share this article Share this article SAN DIEGO, April 28, 2021 /PRNewswire/ Viking Therapeutics, Inc. (Viking) (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced its financial results for the first quarter ended March 31, 2021, and provided an update on its clinical pipeline and other corporate developments.

Poxel SA: Poxel Provides Corporate Update and Reports Cash and Revenue for the First Quarter 2021

Poxel SA: Poxel Provides Corporate Update and Reports Cash and Revenue for the First Quarter 2021 with product launch anticipated in 2021 1 Poxel regained Imeglimin rights from Metavant for US, Europe and other countries not covered by its agreement with Sumitomo Dainippon Pharma and is pursuing next steps to advance its development including partnering activities Poxel continues to prepare for initiation of Phase 2b trial with PXL770 in patients with biopsy-proven NASH and pre-diabetes or type 2 diabetes, expected to commence in H2 2021 PXL065 Phase 2 study ongoing with completion of recruitment expected in mid-2021 and topline data readout in mid-2022 Imeglimin and PXL065 preclinical and clinical data published in peer reviewed journals; PXL770 data accepted for oral and poster presentations at an upcoming scientific conference

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.